leisure time -WSS

leisure time

author：hotspot 2025-09-28 02:28:08 - browse：91

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Global cancer cases to surge 77% by 2050, WHO report says

focus

WSS

Cord blood banking comes at a high cost to babies

Updated Covid vaccine has 54% effectiveness, new study suggests

Unique patient identifier: Experts argue the benefits, pitfalls

Problems with a popular proposal to regulate AI in health care

Top private equity targets in 2023: cardiology, clinical trials, lasers

Cord blood banking comes at a high cost to babies

focus

leisure time

Bluebird and the case for gene therapy profits

focus

Wildfire smoke exposes gaps in outdoor worker protections

Innovation in antibiotics is ailing. 'Brain drain' may kill it

BioMarin wins approval for gene therapy to treat hemophilia A

Why Novartis is going to walk from its acquisition of MorphoSys

Peter Hotez and the public health issue of online harassment

340B reform proposal comes out of Senate working group

Heart attack and stroke risk calculators need revising

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Medical records are filled with copy

AstraZeneca stays mum on Medicare drug pricing negotiations

hotspot

Cord blood banking comes at a high cost to babies

Adopting new red light myopia treatments may be short

A protest over insulin prices is seen as a fight for life

FDA's Pazdur wants cancer trials to range beyond China alone

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

focus

Wikipedia

entertainment

hotspot